Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Collaborator: Procter and Gamble
• Treatments: Darifenacin

Criteria

Inclusion Criteria:

• Symptoms of overactive bladder

• Capable of independent toileting and completing a micturition diary

• Able to comprehend English and follow study procedures and instructions

Exclusion Criteria:

• Post void residual > 100ml/sec

• Urine flow rate (Qmax) <10ml/sec for males only

Other protocol-defined inclusion/exclusion criteria may apply